en Adults Hematology & Oncology Adults Hematology & Oncology پژوهشي Original Article <div style="text-align: justify;"><span style="line-height:2;"><span style="font-size:14px;"><span style="font-family:Times New Roman;"><span style="color:black"><b>Background:</b> The emergence of the COVID-19 pandemic prompted the exploration of convalescent plasma therapy (CPT) as a potential treatment modality. This study provides a comprehensive understanding of adverse events in COVID-19-recovered convalescent plasma (CP) donors for optimizing donor safety and refining donation protocols. The aim is to quantify the type and severity of adverse events associated with CP donation.</span><br> <span style="color:black"><b>Materials and Methods:</b> The present one-year retrospective study was undertaken in the blood center of a tertiary care hospital of Western Uttar Pradesh that was a multicentric site in the ICMR Placid trial and a dedicated COVID hospital during the first and second wave in India. Data was analyzed from donor adverse events (DARs) captured during the study period and evaluated for different parameters namely age, gender, body weight, donor status (first-time donor or previous donor), body mass index, blood volume processed, plasma volume collected and lag time between negative RT-PCR report and plasmapheresis. To determine the significance of variations in rates of DARs, Chi-square test was performed (p-value <0.05 considered significant).</span><br> <span style="color:black"><b>Results:</b> A total of 769 donations were performed in the study duration. The maximum donors were between the age group of 26-33 years with 301 donations were from this age group.&nbsp; Out of 769 donations, 648 donors (84.3%) showed no DARs, while 121 donors (15.7%) experienced adverse reactions.</span></span></span></span></div> <div style="text-align: justify;"><span style="line-height:2;"><span style="font-size:14px;"><span style="font-family:Times New Roman;"><b>Conclusion:</b> Our findings provide essential insights into donor safety, hoping to support and plan future pandemic response strategies against novel infectious diseases.</span></span></span></div> <span style="font-size:11pt"><span style="line-height:115%"><span sans-serif="" style="font-family:Calibri,"><span style="font-size:12.0pt"><span style="line-height:115%"><span new="" roman="" style="font-family:" times=""><i></i></span></span></span></span></span></span> Plasmapheresis, Novel infections, Donor safety, Adverse reactions. 15 23 http://ijbc.ir/browse.php?a_code=A-10-1121-1&slc_lang=en&sid=1 Shalini Bahadur Shalini.bahadur2008@rediffmail.com 100319475328460010855 100319475328460010855 No Department of Pathology, Government Institute of Medical Sciences, Greater Noida Bhumika Gupta drshalinishukla.8@gmail.com 100319475328460010856 100319475328460010856 No Department of Pathology, Government Institute of Medical Sciences, Greater Noida Shalini Shukla Shivani.kalhan69@gmail.com 100319475328460010857 100319475328460010857 No Department of Pathology, Government Institute of Medical Sciences, Greater Noida Paridhi - paridhi.dr@gmail.com 100319475328460010858 100319475328460010858 Yes Department of Pathology, Government Institute of Medical Sciences, Greater Noida Shivani Kalhan drbhumigupta@gmail.com 100319475328460010859 100319475328460010859 No Department of Pathology, Government Institute of Medical Sciences, Greater Noida Madhuvan Gupta drmadhuvangupta@gmail.com 100319475328460010860 100319475328460010860 No Department of Pathology, Government Institute of Medical Sciences, Greater Noida